FY2030 Earnings Estimate for MediWound Issued By Maxim Group

MediWound Ltd. (NASDAQ:MDWD) – Stock analysts at Maxim Group decreased their FY2030 earnings per share (EPS) estimates for MediWound in a research note issued on Friday, May 29th. Maxim Group analyst M. Okunewitch now expects that the biopharmaceutical company will earn $2.81 per share for the year, down from their prior forecast of $2.99. The consensus estimate for MediWound’s current full-year earnings is ($2.49) per share.

Several other brokerages also recently commented on MDWD. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Tuesday, April 21st. Oppenheimer reissued an “outperform” rating and issued a $32.00 target price (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of MediWound in a report on Thursday, May 28th. Finally, Wall Street Zen upgraded MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 30th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, MediWound has an average rating of “Hold” and a consensus target price of $34.00.

MediWound Price Performance

Shares of NASDAQ:MDWD opened at $13.74 on Thursday. The stock has a market capitalization of $176.58 million, a price-to-earnings ratio of -6.08 and a beta of 0.16. MediWound has a fifty-two week low of $13.54 and a fifty-two week high of $22.09. The business’s fifty day moving average price is $16.43 and its two-hundred day moving average price is $17.34.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.42. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $3.37 million. During the same period in the prior year, the business posted ($0.07) earnings per share.

Insider Buying and Selling

In other news, Director David Morton Fox bought 3,537 shares of the business’s stock in a transaction on Monday, June 1st. The shares were purchased at an average price of $14.11 per share, for a total transaction of $49,907.07. Following the purchase, the director owned 22,283 shares of the company’s stock, valued at approximately $314,413.13. The trade was a 18.87% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of MediWound during the 3rd quarter worth approximately $1,042,000. Menora Mivtachim Holdings LTD. boosted its stake in MediWound by 348.8% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company’s stock valued at $1,415,000 after purchasing an additional 61,039 shares during the period. Rosalind Advisors Inc. boosted its stake in MediWound by 84.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock valued at $13,498,000 after purchasing an additional 341,993 shares during the period. UBS Group AG boosted its stake in MediWound by 90.1% in the 4th quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock valued at $2,678,000 after purchasing an additional 68,756 shares during the period. Finally, Quarry LP bought a new stake in MediWound in the 4th quarter valued at $26,000. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.